The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight-loss drug Zepbound as demand soars – and the smaller doses cost 50% less than rival drugs. The more affordable ...

Eli Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent. It started in ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Eli Lilly said it has begun selling vials of the smallest, starter dose of its popular weight-loss drug Zepbound in the United States for $399 for a month on its direct-to-consumer website to ...

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's ...

The investments are part of Lilly's ongoing commitment to expand production for its top-selling diabetes and obesity drugs ...